Table 4 Mean changes between baseline and 90 days for the attributes of survivors in the KyberSept trial: patients in hospital at 90 days and all-survivors
| Â | In-hospital at day 90 | All survivors* | ||||
|---|---|---|---|---|---|---|
Attribute | Placebo (mean ± SD) | AT III (mean ± SD) | P †| Placebo (mean ± SD) AT III (mean ± SD) |  | P †|
Mobility (%) | 33 ± 26 | 38 ± 28 | >0.1 | 49 ± 24 | 51 ± 24 | >0.1 |
Physical activity (%) | 33 ± 27 | 39 ± 26 | >0.1 | 48 ± 23 | 50 ± 23 | >0.1 |
Communication/speech (%) | 42 ± 42 | 61 ± 35 | 0.01 | 52 ± 34 | 57 ± 32 | 0.03 |
Level of alertness (%) | 41 ± 39 | 59 ± 33 | 0.02 | 51 ± 32 | 56 ± 31 | 0.02 |
Energy level (%) | 34 ± 27 | 43 ± 26 | 0.09 | 47 ± 23 | 51 ± 22 | 0.02 |
Overall QoL (%) | 35 ± 28 | 44 ± 27 | >0.1 | 51 ± 23 | 53 ± 23 | >0.1 |
Karnofsky scale (%) | 22 ± 19 | 31 ± 19 | 0.03 | 45 ± 19 | 47 ± 19 | >0.1 |